Phytomedicine publishes the results of Zhong Nanshan team's study on chinese medicine to treat new coronal pneumonia

In order to find and verify which Chinese medicines are effective in the prevention and control of the new coronaepidemic, Zhong Nanshan academician team screened more than 40 kinds of traditional Chinese medicine and traditional Chinese medicine prescriptions, and these studies (including virus suppression tests) laid an important theoretical foundation for the development of clinical trial strainsIn the course of drug screening, the researchers confirmed that traditional Chinese medicines such as Lianhua Qing plague capsules had a good inhibitory effect on cell lesions caused by 2019-nCoV infection, inhibited the activity of new coronaviruses, reduced viral content, and significantly inhibited overexpression of inflammatory factorsThe study was published in the leading journal Pharmacological ResearchBased on this finding, Zhong Nanshan academician, in conjunction with academician scouring Zhang Boli, Academician Li Lanxuan and other clinical experts of Chinese and Western medicine, initiated a forward-looking, randomized, controlled, national multi-center clinical trial to treat the new coronavirus pneumoniathe study was conducted in more than 20 hospitals across the country to treat new coronary pneumonia, and it was not possible to double-blind due to the urgency of epidemic prevention and control;according to the research plan, the selected patients were randomly divided into treatment group and control group (conventional treatment group), with reference to the "new coronavirus pneumonia diagnosis and treatment plan (trial version 4)," the treatment group: routine treatment and even flower plague capsule 4 capsules / times, 3 times / day or particles 1 bag / time, 3 times / day, treatment cycle: 14 daysThe main therapeutic indicators are the main clinical symptoms (fever, fatigue, cough) cure rate, secondary efficacy index for the duration of clinical symptoms, single symptom severity rate and duration, lung CT improvement rate, clinical cure rate, the rate of conversion during the study period, nucleic acid conversion rate and change timeA total of 284 cases were collected in accordance with the study programmetrial data after professional third-party statistical analysis, the results showed that: after 14 days of treatment in the treatment group, the main clinical symptoms (fever, fatigue, cough) cure rate was significantly higher than the control group, in the 7th day of treatment reached 57.7%, the 10th day of treatment reached 80.3%, the 14th day of treatment reached 91.5%Fever, fatigue, cough ingenum duration of single symptoms is also significantly shortened, even the treatment of plague can significantly improve the lung CT imaging abnormality improvement rate, improve the overall clinical cure rateFrom the analysis to reduce the proportion of patients who turned heavy, the treatment group and the control group were significantly lower (2.1% of the plague treatment group and 4.2% of the control group)However, in this clinical trial, even flower plague capsules in the improvement of the new coronary pneumonia nucleic acid transfemininity and shorten the time of transfemininity compared with the control group (conventional treatment group) although shown some advantages, but the difference has not yet reached a statistical significanceAdverse events in the study were mainly light to moderate, and there was no significant difference between the two groups, and there were no serious adverse events associated with the studyThe above series of findings show that the combination of the application of lianhua qing plague capsuleoral 14 days on the basis of conventional treatment can significantly improve the improvement rate of clinical symptoms such as fever, fatigue, cough and so on, significantly improve the lung imaging lesions, shorten the duration of symptoms, improve the clinical cure rate, curb the deterioration of the new coronal disease, and higher safetythe results of this study were published in Phytomedicine," a journal of the Journal of Sci Journal of the Chinese Academy of Sciences, 2020, and is the first forward-looking, randomized, controlled, multi-center clinical study of Chinese medicine to treat new coronavirus infections reported in the international journalThe valuable aspect of this study is that under the circumstances of the epidemic so urgent, Chinese researchers conducted clinical studies in accordance with internationally recognized randomized control standards, confirming that Chinese medicine, represented by lianhua Qing plague capsules, is effective for the auxiliary treatment of the new crownOn April 12, 2020, the State Drug Administration issued the "Drug Supplementapplication Approval" on the application for new indications, approved the "Drug Supplement application approval" on the application for new indications, approved the new coronary pneumonia indications increased by the "functional main treatment" item "in the specification" of "the general treatment of new coronary viral pneumonia, can be used for light, common type of fever, cough, fatigue." "Usage dosage" item to increase the "new coronavirus pneumonia light, ordinary treatment 7-10 days" content, indicating that lianhua qing plague new coronas series of research has been highly recognized by the relevant departments of the stateZhong Nanshan academician's team attaches great importance to the development of traditional Chinese medicine, in the early stage of the epidemic on the positive response to the national call, led a number of medical institutions nationwide to carry out a strict design of Chinese medicine screening research and clinical application discussion, and organized the launch of a randomized controlled clinical trial represented by lianhua qing plague capsulesThe publication of the clinical research results of the study of the new coronal pneumonia published by Phytomedicine, a journal with high impact factors in the field of international botany medicine, is also the international recognition and affirmation of the new crown of Chinese medicine prevention and control, which is of great significance to the internationalization of Chinese medicine(original title: Zhong Nanshan Academician's team of Chinese medicine to treat new coronary pneumonia prospective, randomized, controlled, multi-center clinical research published in Phytomedicine journal)